Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer

Autor:	Shinichi Sakamoto, Minhui Xu, Maki Nagata, Maihulan Maimaiti, Tomohiko Ichikawa, Shuhei Kamada, Hiroki Kitoh, Nobuyoshi Takeuchi, Koichiro Akakura, Hiroomi Nakatsu, Kosuke Higuchi, Hideyasu Matsuyama, Hiroaki Matsumoto, Akira Komiya, Haruhito A. Uchida, Yasutaka Yamada
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty castration resistant prostate cancer 030232 urology & nephrology lcsh:Medicine androgen deprivation therapy Favorable prognosis Article Androgen deprivation therapy 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Internal medicine abiraterone Medicine Enzalutamide Testosterone Serum testosterone enzalutamide business.industry Hazard ratio lcsh:R General Medicine medicine.disease bacterial infections and mycoses prostate cancer Abiraterone chemistry testosterone 030220 oncology & carcinogenesis business
Zdroj:	Journal of Clinical Medicine, Vol 8, Iss 4, p 489 (2019) Journal of Clinical Medicine; Volume 8; Issue 4; Pages: 489 Journal of Clinical Medicine
ISSN:	2077-0383
Popis:	Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/or Abi at Chiba University Hospital and affiliated hospitals were studied. The relationships between progression-free survival (PFS), overall survival (OS), and clinical factors were studied by Cox proportional hazard and Kaplan–Meier models. In the Abi and Enza groups overall, TST ≥ 13 ng/dL (median) (Hazard Ratio (HR) 0.43, p = 0.0032) remained an independent prognostic factor for PFS. In the Enza group, TST ≥ 13 ng/dL (median) was found to be a significant prognostic factor (HR 0.28, p = 0.0044), while, in the Abi group, TST ≥ 12 ng/dL (median) was not significant (HR 0.40, p = 0.0891). TST showed significant correlation with PFS periods (r = 0. 32, p = 0.0067), whereas, for OS, TST ≥ 13 ng/dL (median) showed no significant difference in the Abi and Enza groups overall. According to Kaplan–Meier analysis, a longer PFS at first-line therapy showed a favorable prognosis in the Enza group (p = 0.0429), while no difference was observed in the Abi group (p = 0.6051). The TST level and PFS of first-line therapy may be considered when determining the treatment strategy for CRPC patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef097d51cde4f9f2da55e1c56514d785 https://www.mdpi.com/2077-0383/8/4/489 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.